Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II multicenter study of fully human anti-CD19/CD22 autologous CAR-T cells in relapsed/refractory B-cell non-Hodgkin lymphoma
CTR20212328Phase 2Active
- Sponsor
- Reindeer Biotech
- Start
- Sep 2021
- Modality
- Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CT120 in mature B-cell lymphoma, sponsored by Reindeer Biotech. Primary endpoints: Dose-limiting toxicity, Adverse events and 1 more. Started Sep 2021; status: active.
02
Drugs
CT120
03
Conditions
mature B-cell lymphoma
Beyond the preview
Go deeper on CTR20212328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212328.